ArticleScientific reports2017
Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 59 citations in OpenAlex.
- Advances inMolecular therapy. Nucleic acids · 2026Review
- Feeder-free ex vivo expansion of cord blood-derived natural killer cells for enhanced proliferation and functional maturation.Scientific reports · 2026Article
- Dual Regulatory Functions and Therapeutic Potential of CD48 in Tumor Immunity.Oncology research · 2026Review
- Phenotypic, proteomic, and functional analyses of cytokine-induced memory-like NK cells show two distinct subsets based on CD16 expression.Scientific reports · 2025Article
- Recent advances in feeder-free NK cell expansion as a future direction of adoptive cell therapy.Frontiers in immunology · 2025Review
- Enhancing natural killer cell anti-tumour activity through macrophage manipulation.Frontiers in immunology · 2025Review
- Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34Stem cell research & therapy · 2024Article
- A Critical Role of Culture Medium Selection in Maximizing the Purity and Expansion of Natural Killer Cells.Cells · 2024Article
- Single-domain antibodies as therapeutics for solid tumor treatment.Acta pharmaceutica Sinica. B · 2024Review
- Manufacturing CAR-NK against tumors: Who is the ideal supplier?Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Scalable process development of NK and CAR-NK expansion in a closed bioreactor.Frontiers in immunology · 2024Article
- Nutrient transporter pattern in CD56Frontiers in immunology · 2024Article
- Review
- Review
- Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.Cancer letters · 2023Article
- CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.Journal of experimental & clinical cancer research : CR · 2023Article
- Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells.Scientific reports · 2023Article
- Antitumor effects of NK cells expanded by activation pre‑processing of autologous feeder cells before irradiation in colorectal cancer.Oncology letters · 2023Article
- Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.Scientific reports · 2023Article
- Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are considered a promising strategy for cancer treatment. Various methods for large-scale NK cell expansion have been developed, but they should guarantee that no viable cells are mixed with the expanded NK cells because most methods involve cancer cells or genetically modified cells as feeder cells. We used an anti-CD16 monoclonal antibody (mAb) and irradiated autologous peripheral blood mononuclear cells (PBMCs) (IrAPs) to provide a suitable environment (activating receptor-ligand interactions) for the NK cell expansion. This method more potently expanded NK cells, and the final product was composed of highly purified NK cells with lesser T-cell contamination. The expanded NK cells showed greater upregulation of various activation receptors, CD107a, and secreted larger amounts of interferon gamma. IrAPs expressed NKG2D ligands and CD48, and coengagement of CD16 with NKG2D and 2B4 caused potent NK cell activation and proliferation. The expanded NK cells were cytotoxic toward various cancer cells in vitro and in vivo. Moreover, irradiation or a chemotherapeutic drug further enhanced this antitumor effect. Therefore, we developed an effective in vitro culture method for large-scale expansion of highly purified cytotoxic NK cells with potent antitumor activity using IrAPs instead of cancer cell-based feeder cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.